RLAY
Relay Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 93 | +6 | 111.07M | $2.04B | +13 | −9 |
| Q1 2026 | 92 | +9 | 68.30M | $679.13M | +15 | −7 |
| Q4 2025 | 84 | +2 | 73.82M | $624.52M | +3 | — |
| Q3 2025 | 14 | -1 | 56.07M | $292.70M | — | −2 |
| Q2 2025 | 13 | 0 | 54.62M | $188.99M | +1 | −1 |
| Q1 2025 | 10 | -2 | 33.93M | $88.91M | — | −2 |
| Q4 2024 | 12 | 0 | 26.38M | $108.69M | — | — |
| Q3 2024 | 11 | 0 | 24.01M | $170.03M | +2 | −2 |
| Q2 2024 | 11 | — | 15.37M | $100.25M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 5.04M | — | $32.85M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Norges Bank ✦ (passive) | 3.32M | — | $21.64M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 2.36M | — | $15.42M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Citadel Advisors ✦ | 1.16M | — | $7.58M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 1.15M | — | $7.49M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 909.04K | — | $5.93M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 730.02K | — | $4.76M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Baillie Gifford ✦ | 284.06K | — | $1.85M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 9 | Marshall Wace ✦ | 276.70K | — | $1.80M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 71.91K | — | $468,873 | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 11 | AQR Capital Management ✦ | 67.24K | — | $438,424 | 0.0% | n/c | 1 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 240 holders, 183.00M shares, $1.79B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 48.20K sh · $872,402
Officer · 17.51K sh · $325,354
Officer · 206 sh · $3,968
Officer · 17.72K sh · $335,560
Officer · 8.53K sh · $161,814
Officer, Director · 48.20K sh · $912,889
Officer · 4.51K sh · $90,295
10% owner · 6.00M sh · $116.40M
Officer · 17.72K sh · $349,734
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology